SAITONG capsule (auxiliary blood lipid lowering)
The product has completed animal toxicology, animal efficacy, physical and chemical characteristics and stability tests in the authoritative inspection organization designated by the state market supervision and administration. The human trial was carried out in the designated third class hospital. The product has reliable auxiliary lipid-lowering effect, safety and non-toxic side effects. It is expected to obtain "Jian brand" in 2022.